Buparlisib induces eukaryotic elongation factor-2 expression to cause treatment failure for lung cancer cells

Key Points

• Treatment failure in lung cancer cells is linked to increased eukaryotic elongation factor-2 expression.
• Buparlisib treatment resulted in a significant change in signaling pathways involved in cancer progression.
• Observational analysis highlights the cellular effects of buparlisib on lung cancer treatment outcomes.
• Findings suggest urgent need for alternative approaches in treating lung cancer with buparlisib.